|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Carcinoembryonic Antigen (CEA), Pancreatic Cyst Fluid
Test Code16280
CPT Codes
82378<br>⁠⁠⁠⁠⁠⁠⁠**This test is for Floridam New York, Maryland, and Rhode Island patient testing only**<br>Limited Access Code
Preferred Specimen
1 mL pancreatic fluid submitted in a plastic screw-cap container
Minimum Volume
0.5 mL
Transport Temperature
Frozen
Specimen Stability
Room temperature: Unacceptable
Refrigerated: 72 hours
Frozen: 90 days
Refrigerated: 72 hours
Frozen: 90 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis
Methodology
Immunometric Assay
Setup Schedule
Set up: Mon-Sat; Report available: 2-4 days
Reference Range
See Laboratory Report
Clinical Significance
When used in conjunction with imaging studies, cytology, and other pancreatic cyst fluid tumor markers:
• Distinguishing between mucinous and nonmucinous pancreatic cysts
• Determining the likely type of malignant pancreatic cyst
The diagnosis of pancreatic cyst type is often difficult and may require correlating imaging studies with results of cytologic examination and tumor marker testing performed on cyst aspirates. Various tumor markers have been evaluated to distinguish nonmucinous, nonmalignant pancreatic cysts from mucinous cysts, which have a high likelihood of malignancy. Carcinoembryonic antigen (CEA) has been found to be the most reliable tumor marker for identifying those pancreatic cysts that are likely mucinous. In cyst aspirates, CEA concentrations > or = 200 ng/mL are highly suspicious for mucinous cysts. The greater the CEA concentration, the greater the likelihood that the mucinous cyst is malignant. However, CEA testing does not reliably distinguish between benign, premalignant, or malignant mucinous cysts. CEA test results should be correlated with the results of imaging studies, cytology, other cyst fluid tumor markers (ie, amylase and CA 19-9), and clinical findings for diagnosis.
• Distinguishing between mucinous and nonmucinous pancreatic cysts
• Determining the likely type of malignant pancreatic cyst
The diagnosis of pancreatic cyst type is often difficult and may require correlating imaging studies with results of cytologic examination and tumor marker testing performed on cyst aspirates. Various tumor markers have been evaluated to distinguish nonmucinous, nonmalignant pancreatic cysts from mucinous cysts, which have a high likelihood of malignancy. Carcinoembryonic antigen (CEA) has been found to be the most reliable tumor marker for identifying those pancreatic cysts that are likely mucinous. In cyst aspirates, CEA concentrations > or = 200 ng/mL are highly suspicious for mucinous cysts. The greater the CEA concentration, the greater the likelihood that the mucinous cyst is malignant. However, CEA testing does not reliably distinguish between benign, premalignant, or malignant mucinous cysts. CEA test results should be correlated with the results of imaging studies, cytology, other cyst fluid tumor markers (ie, amylase and CA 19-9), and clinical findings for diagnosis.
